This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Adolescents with high levels of physical ... Previous cross-sectional studies have reported that physically ... (11 Sep 2019)
Offering children a variety of vegetables ... Variety is key to helping children form preferences for ... (11 Sep 2019)
ADHD medication: how much is too much for a ... When children with ADHD don’t respond well to Methylphenidate ... (11 Sep 2019)
Scientists find psychiatric drugs affect gut ... Scientists have found that antidepressants and other psychiatric ... (11 Sep 2019)
Best Strategy for Managing Hypertension and ... In 2009, the Hypertension and Preeclampsia Intervention Trial At ... (12 Sep 2019)
Thursday, 08 August 2019 16:39

Hormonal therapy has a long-term effect in breast cancer Featured

Rate this item
(0 votes)

Researchers at Karolinska Institutet in Sweden have investigated the long-term effect of hormonal therapy in women with the most common types of hormone-sensitive breast cancer. The results, presented in the journal JAMA Oncology, show that the treatment has a protective effect against distant metastatic cancer for both so-called Luminal A and Luminal B breast cancer subtypes, and a long-term effect for women diagnosed with Luminal A cancer.

Estrogen receptor-positive breast cancer is the most common form of breast cancer and means that the tumor grows in response to the female hormone estrogen. Women who develop this form of breast cancer have a long-term risk of distant metastatic spread of the disease and dying from breast cancer. There is however insufficient knowledge of how biological factors in the tumor and hormonal therapy affect this long-term risk.

Researchers at Karolinska Institutet have now investigated the long-term effect of hormonal therapy in women with the two most common types of estrogen receptor-positive breast cancer. The researchers analyzed long-term data with follow-up for at least 20 years for patients in the Stockholm Tamoxifen trial (STO-3) randomised to receive either tamoxifen treatment or no hormonal therapy. In summary, 336 women were diagnosed with so-called Luminal A breast cancer subtype and 126 women with Luminal B subtype.

The results show that patients with Luminal A breast cancer had a relatively small but prolonged risk increase for metastatic cancer, and that tamoxifen treatment significantly reduced this risk for as long as 15 years after diagnosis. Patients with Luminal B subtype were at high risk for metastatic breast cancer during the first five years after diagnosis. In these patients, tamoxifen treatment led to a significantly reduced risk during the first five years, but after that the protective effect of hormonal therapy decreased.

"Our conclusion is that tamoxifen treatment is beneficial for both groups of patients, but that it has a long-term protective effect for patients with Luminal A breast cancer”, says Dr Linda Lindström, a research group leader at Karolinska Institutet’s Department of Biosciences and Nutrition, who coordinated the study. “Patients with Luminal B breast cancer should also be offered hormonal therapy, and our results show a reduced risk of metastatic disease during the first years when the risk is the highest for these patients. We will now proceed to investigate the long-term benefits of hormonal therapy in patients with Luminal A and Luminal B subtype who have been diagnosed with larger and aggressive tumours with spread to the lymph nodes.”



Source: Karolinska Institutet
Full bibliographic information

Assessment of Long-term Survival and Benefit from Tamoxifen Therapy in Patients with Luminal A or Luminal B Breast Cancer’.
JAMA Oncology, online 8 August 2019 

Read 107 times Last modified on Thursday, 08 August 2019 19:08

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…